A vial of the Phase 3 Novavax coronavirus vaccine prepared for use in a trial at St. George's University hospital in London, Oct. 7, 2020. (AP Photo)
A surprise move by the FDA is clouding the future of the Novavax COVID-19 shot (vaccine) and raising concerns about how future strain updates will be handled for all coronavirus vaccines.
The vaccine, known for using a traditional protein-based formula, is the only one of its kind approved for COVID-19 in the U.S. However, the FDA is now requiring Novavax to conduct a fresh clinical trial after granting full approval. Novavax responded, stating that it believes its shot still meets approval standards.
New Trial Demand for Novavax Sparks Confusion
A social media post over the weekend from FDA Commissioner Marty Makary deepened the uncertainty. He described the updated Novavax vaccine as a “new product,” implying a new clinical trial would be necessary for any update — something experts warn could create delays before the fall season.
“If every strain change means a new trial, we’d never have vaccines ready in time,” said Dr. Jesse Goodman, former FDA vaccine director and current Georgetown University professor.
Internal Disputes Surface at the FDA
This decision follows internal strife at the agency. The FDA’s longtime vaccine chief recently exited over disagreements with Health Secretary Robert F. Kennedy Jr., a Trump appointee. Kennedy, while promising not to alter the national vaccine schedule, has canceled expert panel meetings and revived the debunked theory linking vaccines to autism.
Makary’s comments suggest a shift from prior FDA norms, where annual updates to COVID shots were treated like flu vaccine changes — minor tweaks, not entirely new products.
Novavax COVID-19 Shot in Limbo Despite Promising Data
Novavax's vaccine had shown high effectiveness in a clinical trial of nearly 30,000 participants. Though still under emergency use authorization in the U.S., it was expected to gain full approval by April 1. According to insiders, FDA scientists were on track to approve it — until Trump administration officials reportedly told them to pause the process.
Since then, Novavax has been in talks with the FDA to navigate these unexpected requirements.
mRNA Vaccines Uncertain Amid Changing Policy
So far, there’s no clarity on whether these new rules will affect Pfizer and Moderna’s mRNA vaccines. However, an administration spokesperson hinted that all COVID-19 vaccines may face added scrutiny going forward.
“With the current lower threat level of COVID, the urgency to fast-track boosters is gone,” said HHS spokesperson Andrew Nixon.
Vaccine Experts Warn of Policy Shift
Traditionally, the FDA has treated COVID-19 strain updates similarly to the flu — not as new products. Dr. Paul Offit, a vaccine specialist at the Children’s Hospital of Philadelphia, emphasized that even updated vaccines go through tests in small groups to ensure they trigger protective antibody responses and remain safe.
Nixon added that flu shots may not fall under these new guidelines, calling them “tried and tested for more than 80 years.”
Legal Risks Ahead for the FDA
Experts warn that if political interference leads to irregular approval processes, the FDA could face legal challenges. Drugmakers or patients — especially those allergic to mRNA shots — could sue.
Former Health Secretary Xavier Becerra reminded the public of the vast real-world data already available.
“We had delivered 700 million COVID shots when I left,” he said. “That’s a massive clinical trial on its own.”
The FDA’s next moves could reshape how America updates and approves vaccines — not just for COVID, but possibly beyond.
